Sodium Oligomannate (GV-971) for Alzheimer’s Disease

Overview

flowchart TD
    TNF["TNF"] -->|"associated with"| NLRP3["NLRP3"]
    TNF["TNF"] -->|"therapeutic target"| AKT1["AKT1"]
    TNF["TNF"] -->|"activates"| MTOR["MTOR"]
    TNF["TNF"] -->|"activates"| AKT["AKT"]
    TNF["TNF"] -->|"activates"| PI3K["PI3K"]
    TNF["TNF"] -->|"activates"| BDNF["BDNF"]
    TNF["TNF"] -->|"activates"| STAT3["STAT3"]
    TNF["TNF"] -->|"therapeutic target"| AKT["AKT"]
    TNF["TNF"] -->|"therapeutic target"| TP53["TP53"]
    TNF["TNF"] -->|"inhibits"| PI3K["PI3K"]
    TNF["TNF"] -->|"inhibits"| AKT["AKT"]
    TNF["TNF"] -->|"activates"| ASTROCYTES["ASTROCYTES"]
    TNF["TNF"] -->|"activates"| Tumor["Tumor"]
    TNF["TNF"] -->|"activates"| Apoptosis["Apoptosis"]
    style TNF fill:#4fc3f7,stroke:#333,color:#000

<table class=“infobox infobox-therapeutic”> <tr> <th class=“infobox-header” colspan=“2”>Sodium Oligomannate (GV-971) for Alzheimer’s Disease</th> </tr> <tr> <td class=“label”>Parameter</td> <td>Details</td> </tr> <tr> <td class=“label”>Dosage</td> <td>450 mg twice daily (900 mg total daily)</td> </tr> <tr> <td class=“label”>Route</td> <td>Oral</td> </tr> <tr> <td class=“label”>Formulation</td> <td>Capsule</td> </tr> <tr> <td class=“label”>Duration</td> <td>Chronic, long-term treatment</td> </tr> <tr> <td class=“label”>Food Interaction</td> <td>Take with or without food</td> </tr> <tr> <td class=“label”>Region</td> <td>Status</td> </tr> <tr> <td class=“label”>China (NMPA)</td> <td>Approved (conditional)</td> </tr> <tr> <td class=“label”>US (FDA)</td> <td>Fast Track Designation</td> </tr> <tr> <td class=“label”>US (FDA)</td> <td>Phase 3 planned</td> </tr> <tr> <td class=“label”>EU (EMA)</td> <td>Not yet filed</td> </tr> <tr> <td class=“label”>Feature</td> <td>GV-971</td> </tr> <tr> <td class=“label”>Target</td> <td>Gut-brain axis</td> </tr> <tr> <td class=“label”>Type</td> <td>Disease-modifying</td> </tr> <tr> <td class=“label”>Route</td> <td>Oral</td> </tr> <tr> <td class=“label”>Approval</td> <td>China</td> </tr> <tr> <td class=“label”>Mechanism</td> <td>Microbiome modulation</td> </tr> </table>

Sodium Oligomannate (GV-971, trade name: Oligomannate) is a disease-modifying therapy for Alzheimer’s disease developed by Green Valley Pharmaceuticals (Shanghai, China). It received conditional approval from the China National Medical Products Administration (NMPA) in November 2019 for the treatment of mild to moderate Alzheimer’s disease, making it the first new disease-modifying treatment approved anywhere in the world since 2003[@xing2021][@china2019].

GV-971 is a marine-derived acidic oligosaccharide extracted from brown algae (Ascophyllum nodosum). Unlike previous Alzheimer’s drugs that target amyloid-beta or tau pathology directly, GV-971 takes a novel approach by modulating the gut-brain axis through alteration of gut microbiota composition[“@wang2019”].

Mechanism of Action

Gut Microbiota Modulation

GV-971 operates through a distinctive gut-brain axis mechanism:

Gut Microbiome Alteration: GV-971 reduces pro-inflammatory gut bacteria (such as Escherichia/Shigella) while increasing beneficial bacteria (such as Bifidobacterium and Lactobacillus)[@wang2019]
Reduction of Peripheral Inflammation: By modulating gut microbiota, GV-971 decreases the levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in the peripheral blood[@wang2019]
Neuroinflammation Reduction: Lower peripheral inflammation leads to reduced neuroinflammation in the brain through the gut-brain immune pathway[@wang2019]
Amyloid Plaque Reduction: Studies show GV-971 can reduce amyloid-beta plaque deposition in the hippocampus and cortex[@li2020]

Key Molecular Targets

Gut microbiota: Reduces Escherichia/Shigella populations
Peripheral cytokines: Decreases IL-1β, IL-6, TNF-α
Brain microglia: Modulates microglial activation states
Amyloid-beta: Reduces plaque burden in AD models

Clinical Evidence

Phase 3 Trial (Green Memory Study)

The pivotal Phase 3 trial (NCT02293915) enrolled 818 patients with mild to moderate Alzheimer’s disease (MMSE score 10-26) in China[@xiao2021]:

Study Design: 36-week, randomized, double-blind, placebo-controlled
Dosage: 450 mg twice daily (900 mg total daily)
Primary Endpoint: Change from baseline in ADAS-Cog score at week 36

Results:

Significant improvement in cognitive function vs. placebo (difference: -2.15 points on ADAS-Cog at week 36, p=0.0004)
Benefits observed as early as week 4
Good safety profile with mostly mild adverse events

Supporting Studies

Phase 2 Trial: Showed dose-dependent cognitive benefits with good tolerability[@zhang2018]
Post-hoc Analyses: Suggested benefits in patients with mild to moderate AD
Real-world Data: Chinese real-world studies have reported continued use and monitoring[@green]

Dosing and Administration

Safety and Adverse Effects

Common Adverse Events

Nausea (most common)
Diarrhea
Dizziness
Headache
Fatigue

Safety Profile

GV-971 demonstrated a favorable safety profile in clinical trials:

No major organ toxicity
Low rates of serious adverse events
No significant differences in discontinuation rates vs. placebo
Drug-related adverse events were mostly mild to moderate

Regulatory Status

The FDA Fast Track designation was granted in 2020 to facilitate development and expedite review[@fda2020]. Green Valley has been conducting additional clinical trials to meet international regulatory requirements.

Comparison with Other AD Therapies

Research Pipeline

Ongoing Studies

Global Phase 3 Trials: Planning or recruiting for international trials
Combination Therapy: Studies exploring GV-971 combined with standard AD treatments
Biomarker Studies: Investigating predictive biomarkers for treatment response
Mechanism Studies: Further elucidation of gut-brain signaling pathways

Future Directions

Biomarker Development: Identifying patients most likely to respond
Combination Approaches: Testing with cholinesterase inhibitors or other disease-modifying therapies
Early Intervention: Potential use in prodromal AD or preclinical populations
Mechanistic Biomarkers: Gut microbiome and inflammatory markers as treatment response predictors

Allen Brain Atlas Resources

Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions
Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy
Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury

External Links

References

Xing XY, et al, Sodium oligomannate: a new therapeutic option for Alzheimer’s disease (2021)
Unknown, China approves GV-971, the first new drug for Alzheimer’s disease in 17 years (2019)
Wang X, et al, Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression (2019)
Li C, et al, GV-971 ameliorates amyloid-beta pathology and cognitive deficits in APP/PS1 transgenic mice (2020)
Xiao S, et al, Green Memory: a phase 3 trial of GV-971 in mild-to-moderate Alzheimer’s disease (2021)
Zhang J, et al, A randomized, double-blind, placebo-controlled phase II trial of GV-971 in mild-to-moderate Alzheimer’s disease (2018)
Unknown, Green Valley Pharmaceuticals - GV-971 Research (n.d.)
Unknown, FDA grants Fast Track designation for GV-971 (2020)

Pathway Diagram

The following diagram shows the key molecular relationships involving Sodium Oligomannate (GV-971) for Alzheimer’s Disease discovered through SciDEX knowledge graph analysis:

graph TD
    IL_6["IL-6"] -->|"associated with"| TNF["TNF"]
    IL_6["IL-6"] -.->|"inhibits"| TNF["TNF"]
    MICROGLIA["MICROGLIA"] -->|"activates"| TNF["TNF"]
    NEURODEGENERATION["NEURODEGENERATION"] -->|"associated with"| TNF["TNF"]
    IL_6["IL-6"] -->|"activates"| TNF["TNF"]
    TNF__["TNF-Α"] -->|"activates"| TNF["TNF"]
    MICROGLIA["MICROGLIA"] -->|"associated with"| TNF["TNF"]
    NLRP3["NLRP3"] -.->|"inhibits"| TNF["TNF"]
    IL_6["IL-6"] -->|"expressed in"| TNF["TNF"]
    CASP3["CASP3"] -->|"associated with"| TNF["TNF"]
    INFLAMMATION["INFLAMMATION"] -->|"activates"| TNF["TNF"]
    APP["APP"] -->|"associated with"| TNF["TNF"]
    BAX["BAX"] -->|"activates"| TNF["TNF"]
    AKT["AKT"] -->|"associated with"| TNF["TNF"]
    NEURODEGENERATION["NEURODEGENERATION"] -->|"activates"| TNF["TNF"]
    style IL_6 fill:#ce93d8,stroke:#333,color:#000
    style TNF fill:#ce93d8,stroke:#333,color:#000
    style MICROGLIA fill:#ce93d8,stroke:#333,color:#000
    style NEURODEGENERATION fill:#ce93d8,stroke:#333,color:#000
    style TNF__ fill:#ce93d8,stroke:#333,color:#000
    style NLRP3 fill:#ce93d8,stroke:#333,color:#000
    style CASP3 fill:#ce93d8,stroke:#333,color:#000
    style INFLAMMATION fill:#ce93d8,stroke:#333,color:#000
    style APP fill:#ce93d8,stroke:#333,color:#000
    style BAX fill:#ce93d8,stroke:#333,color:#000
    style AKT fill:#ce93d8,stroke:#333,color:#000

Sodium Oligomannate (GV-971) for Alzheimer's Disease